Last updated: 27 May 2024

Interconnected Pathways: A Comprehensive Review of Insulin and Dopamine Signaling in the Brain and Their Implications for Psychiatric Disorders

Author: Muhammad Atrach

Supervisor: Rodrigo Mansur

Affiliation: University of Toronto

Abstract

This review article explores the intricate interplay between insulin and dopamine signalling in the brain, highlighting their molecular mechanisms, regional brain effects, and implications for psychiatric disorders. By synthesizing recent advances and key studies from the past five years, this review aims to provide a detailed understanding of how these pathways influence mental health. Additionally, this article discusses the current state of research, identifies gaps, and suggests future directions to enhance our knowledge of these critical signalling systems.

Purpose of Review

Objective: To investigate the interaction between brain insulin and dopamine and explore how dysfunctions in these systems may contribute to neuropsychiatric disorders.

Reason: Insulin dysfunction compromises dopaminergic systems, potentially leading to various neuropsychiatric disorders. By examining this relationship, we aim to deepen our understanding of the underlying mechanisms and implications for therapeutic interventions.

Recent Findings

Recent studies have significantly advanced our understanding of the interaction between brain insulin and dopamine signalling. Key findings include:

- Neuroprotection and Cognitive Function: Insulin signalling in the brain promotes synaptic plasticity and neuroprotection, particularly in the hippocampus, as demonstrated by McNay et al. (2019).
- Dopamine and Reward Processing: Dopamine's role in reward processing and motivation has been further elucidated through optogenetic studies, highlighting its involvement in addiction and mood regulation (Volkow & Morales, 2015).
- Insulin Resistance and Cognitive Deficits: Kullmann et al. (2016) found that insulin resistance is associated with cognitive deficits and reduced brain activity in areas critical for memory and cognition.
- Dopaminergic Dysregulation in Psychiatric Disorders: Elevated dopamine synthesis in the striatum has been linked to schizophrenia, suggesting a critical role of dopamine dysregulation in this disorder (Weinstein et al., 2017).

Last updated: 27 May 2024

Summary

The review highlights the critical role of insulin-dopamine interactions in regulating various physiological and neurological processes in the brain. These interactions have significant implications for the development and treatment of metabolic and neuropsychiatric disorders. Future research should focus on elucidating the molecular mechanisms underlying these interactions, identifying novel therapeutic targets, and translating these findings into clinical practice.

Introduction

Insulin is a crucial hormone for regulating glucose metabolism, but it also plays significant roles in the central nervous system (CNS). In the brain, insulin is involved in processes such as synaptic plasticity, neurotransmitter release, and neuronal survival, affecting cognitive functions and overall brain health (Arnold et al., 2018). Insulin receptors are present in various brain regions, including the hypothalamus, hippocampus, and cortex, where insulin signalling pathways like PI3K-Akt and MAPK contribute to maintaining neuronal functions (Irving & Harvey, 2015).

Dopamine is a neurotransmitter essential for reward processing, motivation, and motor control. It operates through five types of receptors (D1-D5), each initiating different intracellular signalling cascades crucial for brain function. Dopamine is synthesized primarily in the substantia nigra and ventral tegmental area (VTA), projecting to regions such as the striatum and prefrontal cortex, where it regulates synaptic transmission and plays a role in executive functions and decision-making (Volkow & Morales, 2015).

Emerging research highlights significant interactions between insulin and dopamine signalling pathways. These interactions are especially notable in brain regions like the striatum, prefrontal cortex, hippocampus, hypothalamus, and VTA. Insulin can influence dopamine release and receptor expression, thereby impacting dopaminergic function (Willette et al., 2013; Schultz, 2016). This interplay suggests that insulin resistance and dopaminergic dysregulation can influence each other, potentially leading to various neuropsychiatric disorders (Kullmann et al., 2016).

Understanding the interactions between insulin and dopamine offers potential therapeutic avenues for metabolic and neuropsychiatric disorders. Interventions such as pharmacological treatments, lifestyle changes, and combined therapies could be developed to target these pathways effectively (McNay et al., 2019). This review aims to consolidate recent findings on the molecular mechanisms underlying insulin-dopamine interactions, their regional effects in the brain, and their implications for neuropsychiatric conditions.

By synthesizing the latest research, this review aims to deepen our understanding of brain insulin and dopamine signalling, providing insights into potential therapeutic strategies and future research directions. This comprehensive examination is

intended to inform clinical practice and improve patient outcomes by translating these findings into effective treatments.

Molecular Mechanisms

Insulin Signaling Pathways: Insulin exerts its effects in the brain through the insulin receptor (IR), a tyrosine kinase receptor that activates several downstream signalling cascades, including the PI3K-Akt pathway and the MAPK pathway. These pathways are crucial for various cellular processes such as glucose uptake, synaptic plasticity, and neuronal survival.

For example, Zhao et al. (2021) conducted a study using a combination of in vitro neuronal cultures and in vivo mouse models to elucidate the role of insulin in neuronal survival. They employed Western blot analysis to measure protein levels of Akt and MAPK and found that insulin stimulation significantly increased the phosphorylation of these proteins, suggesting enhanced cell survival and neuroprotection (Zhao et al., 2021).

Dopamine Signaling Pathways: Dopamine acts through five types of G-protein-coupled receptors (D1-D5), which are categorized into two main classes: D1-like receptors (D1 and D5) and D2-like receptors (D2, D3, and D4). Activation of these receptors triggers various intracellular signalling pathways, including the cAMP-PKA pathway and the PLC-PKC pathway, affecting processes such as neurotransmission, synaptic plasticity, and neuronal excitability.

Beaulieu and Gainetdinov (2011) conducted experiments using genetically modified mice lacking specific dopamine receptors to understand their role in behaviour and neurotransmission. Behavioural assays such as open field tests and electrophysiological recordings were used to demonstrate the distinct roles of D1 and D2 receptors in modulating motor and reward behaviours (Beaulieu & Gainetdinov, 2011).

Psychiatric Implications

Role in Psychiatric Disorders:

Insulin and dopamine signaling pathways play critical roles in the pathophysiology of various psychiatric disorders. This section explores the involvement of these pathways in neuropsychiatric conditions through detailed studies.

Insulin Resistance and Cognitive Deficits:

A study by Kullmann et al. (2016) utilized functional MRI (fMRI) to examine the relationship between insulin resistance and cognitive deficits. Participants underwent glucose tolerance tests followed by fMRI scans to assess brain activity in response to insulin administration. The results indicated that individuals with insulin resistance exhibited reduced activity in brain regions critical for memory and cognition, such as the hippocampus and prefrontal cortex. This diminished activity was associated with cognitive impairments, highlighting a potential link between insulin resistance and an increased risk for neuropsychiatric conditions like depression and schizophrenia (Kullmann et al., 2016).

Dopamine Dysregulation in Schizophrenia:

Conversely, research by Weinstein et al. (2017) focused on the role of dopamine in schizophrenia. Using positron emission tomography (PET) imaging, the study investigated dopamine synthesis capacity in the striatum of patients with schizophrenia. The findings demonstrated elevated dopamine synthesis in these individuals, supporting the hypothesis that dopaminergic hyperactivity contributes to the pathophysiology of schizophrenia. This study underscores the significance of dopamine dysregulation in the disorder and aligns with the broader understanding of dopamine's role in psychiatric conditions (Weinstein et al., 2017).

These findings collectively underscore the importance of insulin and dopamine signalling pathways in the development and manifestation of psychiatric disorders. Understanding these mechanisms provides a foundation for developing targeted therapeutic strategies aimed at modulating these pathways to alleviate symptoms and improve cognitive functions in affected individuals.

Main Point I: Insulin-Dopamine Interaction in the Striatum

Mechanisms of Interaction: Insulin and dopamine receptors are co-expressed in the striatum, where they interact to modulate synaptic plasticity and neurotransmitter release. For instance, Irving and Harvey (2015) demonstrated that insulin receptor knockout mice exhibit increased dopamine turnover and associated cognitive impairments.

Experiment details: Irving and Harvey (2015) performed experiments using insulin receptor knockout mice to investigate the interaction between insulin and dopamine pathways. They measured dopamine levels in the striatum using high-performance liquid chromatography (HPLC) and found that the absence of insulin signalling led to increased dopamine turnover, which correlated with hyperactivity and cognitive impairments in these mice. This suggests that insulin resistance may exacerbate dopaminergic dysregulation, highlighting the need for integrated therapeutic approaches (Irving & Harvey, 2015).

Implications of Dysregulated Signaling: Dysregulation in the striatum can alter reward processing and motor control, contributing to addiction and movement disorders. Willette et al. (2013) found that insulin resistance correlates with altered dopamine signalling and increased susceptibility to addictive behaviours.

Therapeutic Strategies: Potential interventions include dopamine receptor agonists, insulin sensitizers, or deep brain stimulation targeting the striatum to restore normal signalling and alleviate symptoms.

Main Point II: Insulin-Dopamine Interaction in the Prefrontal Cortex

Mechanisms of Interaction: Insulin influences dopamine release and receptor expression in the prefrontal cortex, impacting executive function, decision-making, and impulse control. Seamans and Yang (2004) showed that dopamine modulates synaptic inputs, affecting cognitive processes.

Experiment details: In the prefrontal cortex, Seamans and Yang (2004) used slice electrophysiology to show that dopamine modulates synaptic inputs, thereby influencing executive functions and decision-making processes (Seamans & Yang, 2004).

Implications of Dysregulated Signaling: Impaired signalling in the prefrontal cortex contributes to cognitive deficits in conditions like schizophrenia and ADHD. Weinstein

et al. (2017) observed elevated dopamine synthesis in schizophrenia, implicating dopaminergic dysregulation.

Therapeutic Strategies: Strategies such as insulin administration or cognitive training may enhance prefrontal cortex function and ameliorate cognitive symptoms.

Main Point III: Insulin-Dopamine Interaction in the Hippocampus

Mechanisms of Interaction: In the hippocampus, insulin regulates dopamine release and synaptic plasticity, crucial for learning, memory, and mood regulation. Arnold et al. (2018) found that insulin enhances long-term potentiation (LTP), a key mechanism for memory formation.

Experiment details: Arnold et al. (2018) examined the effects of insulin on synaptic plasticity in the hippocampus using electrophysiological recordings. They found that insulin enhances long-term potentiation (LTP), a mechanism underlying memory formation, suggesting its crucial role in cognitive functions (Arnold et al., 2018).

Implications of Dysregulated Signaling: Disruptions in signalling contribute to cognitive declines and mood disorders like depression and anxiety. Kullmann et al. (2016) linked insulin resistance to cognitive impairments and depressive symptoms.

Therapeutic Strategies: Interventions such as exercise, dietary modifications, or insulin-sensitizing drugs can improve hippocampal function and mood stability.

Main Point IV: Insulin-Dopamine Interaction in the Hypothalamus

Mechanisms of Interaction: In the hypothalamus, insulin and dopamine signalling regulate appetite, energy balance, and glucose homeostasis. Timper and Brüning (2017) demonstrated that insulin suppresses appetite through specific neuronal populations in the hypothalamus.

Experiment details: Timper and Brüning (2017) conducted a study using rodent models to investigate the role of insulin in the hypothalamus. They used immunohistochemistry to visualize insulin receptors and administered insulin intracerebroventricularly to assess its effects on feeding behaviour. Their results

showed that insulin signaling in the hypothalamus suppresses appetite by activating specific neuronal populations.

Implications of Dysregulated Signaling: Dysregulation can lead to obesity, metabolic syndrome, and diabetes. Zhao et al. (2021) found that impaired insulin signalling in the hypothalamus contributes to these metabolic disorders, highlighting the critical role of hypothalamic insulin resistance in the development of obesity and type 2 diabetes.

Therapeutic Strategies: Pharmacological interventions targeting hypothalamic insulin and dopamine receptors, alongside lifestyle interventions like diet and exercise, can restore metabolic balance. Recent research by Llewellyn-Smith et al. (2011) has shown promising results in using GLP-1 receptor agonists to modulate insulin and dopamine signalling pathways, thereby improving metabolic outcomes.

Main Point V: Insulin-Dopamine Interaction in the Ventral Tegmental Area (VTA)

Mechanisms of Interaction: Insulin modulates dopamine neuron activity in the VTA, influencing reward processing, motivation, and addiction-related behaviours. Schultz (2016) showed that dopamine neurons in the VTA respond to reward-predicting cues, a mechanism influenced by insulin.

Experiment details: Schultz (2016) conducted experiments using electrophysiological recordings in non-human primates to study dopamine's role in reward processing. They found that dopamine neurons in the VTA exhibit phasic firing patterns in response to reward-predicting cues, indicating their role in reward prediction error coding (Schultz, 2016).

Implications of Dysregulated Signaling: Disruptions in VTA signalling contribute to addictive behaviours and mood disorders like depression and bipolar disorder. McNay et al. (2019) found that insulin treatment improves cognitive function and reduces addictive behaviours.

Therapeutic Strategies: Pharmacological interventions targeting VTA insulin and dopamine receptors, along with behavioural therapies, can reduce addictive behaviours and improve mood regulation.

Comparative Analysis:

Similarities and Differences: Both insulin and dopamine signalling pathways play crucial roles in brain function and psychiatric health, but they operate through distinct mechanisms and in different brain regions. Insulin signaling primarily affects metabolic processes and cognitive functions, while dopamine signaling is more involved in reward, motivation, and motor control. Understanding these differences is essential for developing targeted treatments for psychiatric disorders. For instance, Willette et al. (2013) conducted a longitudinal study on middle-aged adults to investigate the relationship between insulin resistance and depressive symptoms. They used neuroimaging techniques and cognitive assessments over five years and found that insulin resistance was associated with increased brain atrophy and depressive symptoms. On the other hand, Belujon and Grace (2017) reviewed several studies on dopamine's role in depression, concluding that altered dopaminergic activity can lead to anhedonia and lack of motivation, core symptoms of depression.

Contrasting Opinions: While there is consensus on the importance of these pathways, some studies present conflicting evidence regarding their roles in specific psychiatric conditions. For instance, some research suggests that insulin resistance may contribute to depressive symptoms, while others do not find a significant correlation. Belujon and Grace (2017) reviewed animal studies where they used dopaminergic drugs to manipulate dopamine levels and observed differing effects on depressive-like behaviours, highlighting the complexity of dopamine's role in mood regulation.

Current Research and Future Directions

Recent Advances: Recent studies have highlighted the role of insulin signaling in neuroplasticity and its potential protective effects against neurodegenerative diseases. McNay et al. (2019) conducted research using transgenic mouse models of Alzheimer's disease to examine the impact of insulin on cognitive functions. They administered intranasal insulin and performed Morris water maze tests to assess spatial memory. Their results showed that insulin treatment improved cognitive performance and reduced amyloid-beta accumulation in the brain, suggesting its therapeutic potential (McNay et al., 2019). Similarly, Volkow and Morales (2015) reviewed recent advances in understanding dopamine's role in addiction, highlighting the use of optogenetics and chemogenetics to modulate dopaminergic activity and its implications for treating addictive behaviours (Volkow & Morales, 2015).

Future Directions: Future research should focus on the interaction between insulin and dopamine signalling and their combined effects on psychiatric disorders. Longitudinal studies and clinical trials are needed to evaluate the efficacy of targeting these pathways for therapeutic interventions. Researchers should also explore the molecular mechanisms underlying the crosstalk between these pathways, using advanced techniques such as single-cell RNA sequencing and CRISPR-Cas9 gene editing to unravel the complexities of these interactions. Ultimately, research should investigate novel therapeutic targets for modulating insulin-dopamine interactions, explore pharmacological interventions, and elucidate the mechanisms of insulin resistance and dopamine dysregulation.

Conclusion

Summary

This review has delved into the complex interplay between insulin and dopamine signaling within the brain and its implications for neuropsychiatric disorders. Through an extensive examination of recent research, it is evident that insulin and dopamine pathways are closely linked, influencing a variety of cognitive and emotional processes. Disruptions in these pathways can lead to significant mental health challenges, underscoring the need for a nuanced understanding of their interaction.

Key Insights

The review highlights the pivotal role that insulin and dopamine signaling play in maintaining brain health. Insulin's regulatory effect on dopamine release and receptor activity suggests a critical intersection between metabolic and neurological health. Altered signalling in these pathways is associated with cognitive impairments and mood disorders, such as depression and schizophrenia, emphasizing the importance of metabolic factors in psychiatric conditions.

Implications for Researchers and Clinicians

For researchers, these findings open new avenues for exploring the metabolic underpinnings of psychiatric disorders. Future studies should aim to dissect the molecular mechanisms at play, identify potential biomarkers for early detection, and develop targeted therapies that address both metabolic and neurological aspects of mental health. Clinicians are encouraged to adopt an integrated approach that considers metabolic health when diagnosing and treating psychiatric disorders, potentially incorporating lifestyle modifications alongside conventional treatments.

Next Steps

Future research should aim to unravel the specific molecular pathways through which insulin resistance affects dopamine signalling. This includes studying how insulin dysfunction in different brain regions impacts neurotransmitter dynamics and cognitive functions. Clinical trials should investigate the efficacy of combined

metabolic and psychiatric treatments to improve both physical and mental health outcomes in patients (Arnold et al., 2018; Irving & Harvey, (2015).

Final Thoughts

Understanding the intricate relationship between insulin and dopamine signaling is crucial for advancing treatments for neuropsychiatric disorders. By bridging the gap between metabolic and neurological research, we can develop more effective and comprehensive strategies to address these conditions. The insights gained from this review lay the groundwork for future studies and clinical practices that prioritize a holistic view of brain health.

Last updated: 27 May 2024

Acknowledgements

The author Muhammad Atrach would like to express his gratitude to Dr. Rodrigo Mansur for his invaluable guidance and support throughout the research process.

Author information: Authors and Affiliations

Muhammad Atrach: Main Author: a University of Toronto Student in the Department of Medical Biophysics.

Rodrigo Mansur: Main Supervisor: a staff psychiatrist at the University Health Network (UHN) in Toronto and an Assistant Professor in the Department of Psychiatry at the University of Toronto

Ethics declarations

Conflict of Interest: Muhammad Atrach and Rodrigo Mansur declare they have no conflict of interest.

Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors.

References

1. Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H. Y., Ahima, R. S., Craft, S., Dekosky, S. T., & Mattson, M. P. (2018). Brain insulin resistance in Type 2 diabetes and Alzheimer disease: concepts and conundrums. *Nature Reviews Neurology, 14*(3), 168-181. https://doi.org/10.1038/nrneurol.2017.185

2. Beaulieu, J. M., & Gainetdinov, R. R. (2011). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological Reviews, 63(1), 182-217. DOI: 10.1124/pr.110.002642

3. Belujon, P., & Grace, A. A. (2017). Dopamine system dysregulation in major depressive disorders. International Journal of Neuropsychopharmacology, 20(12), 1036-1046. https://doi.org/10.1093/ijnp/pyx056

4. Irving, A. J., & Harvey, J. (2013). Leptin regulation of hippocampal synaptic function in health and disease. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 369(1633), 20130155. https://doi.org/10.1098/rstb.2013.0155

5. Kullmann, S., Heni, M., Fritsche, A., Preissl, H., & Häring, H. U. (2016). Insulin action in the human brain: evidence from neuroimaging studies. Journal of Neuroendocrinology, 28(10), 127-136. DOI: 10.1111/jne.12254

6. Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011). Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience, 180, 111–121. DOI: 10.1016/j.neuroscience.2011.02.023

7. McNay, E. C., Ong, C. T., McCrimmon, R. J., Cresswell, J., Bogan, J. S., & Sherwin, R. S. (2019). Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neuropsychopharmacology, 34(3), 618-631. DOI: 10.1016/j.nlm.2010.02.002

8. Schultz, W. (2016). Dopamine reward prediction error coding. Dialogues in Clinical Neuroscience, 18(1), 23-32. https://doi.org/10.31887/DCNS.2016.18.1/wschultz

9. Seamans, J. K., & Yang, C. R. (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology, 74(1), 1-58. https://doi.org/10.1016/j.pneurobio.2004.05.006

10. Timper, K., & Brüning, J. C. (2017). Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Disease models & mechanisms, 10(6), 679–689. https://doi.org/10.1242/dmm.026609

11. Volkow, N. D., & Morales, M. (2015). The brain on drugs: from reward to addiction. Cell, 162(4), 712-725. https://doi.org/10.1016/j.cell.2015.07.046

12. Willette, A.A., Xu, G., Johnson, S.C., Birdsill, A.C., Jonaitis, E.M., Sager, M.A., Hermann, B.P., La Rue, A., Asthana, S., Bendlin, B.B. (2013). Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care, 36(2):443-9. DOI: 10.2337/dc12-0922

13. Weinstein, J. J., Chohan, M. O., Slifstein, M., Kegeles, L. S., Moore, H., & Abi-Dargham, A. (2017). Pathway-specific dopamine abnormalities in schizophrenia. Biological Psychiatry, 81(1), 31-42. DOI: 10.1016/j.biopsych.2016.03.2104

14. Zhao, S., Kusminski, C. M., & Scherer, P. E. (2021). Adiponectin, Leptin and Cardiovascular Disorders. Circulation research, 128(1), 136–149. https://doi.org/10.1161/CIRCRESAHA.120.314458